Clinical Trials in Saint Petersburg, Russia
15 recruiting
Showing 1–18 of 18 trials
Recruiting
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
Breast Cancer
Novartis Pharmaceuticals2,766 enrolled34 locationsNCT06930859
Recruiting
Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer453 enrolled82 locationsNCT03460977
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Chronic Lymphocytic LeukemiaMantle Cell LymphomaFollicular Lymphoma+1 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
Prostate Cancer
AstraZeneca400 enrolled18 locationsNCT07052578
Recruiting
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
Breast Cancer
Novartis Pharmaceuticals240 enrolled5 locationsNCT06905301
Recruiting
Phase 1Phase 2
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC110 enrolled48 locationsNCT04938817
Recruiting
Phase 4
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Cognitive FunctionMotor FunctionContrast Media
Guerbet2,076 enrolled51 locationsNCT04373564
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
Breast Cancer MetastaticRenal Cell Carcinoma MetastaticProstate Cancer Metastatic+2 more
Kidney Cancer Research Bureau58 enrolled5 locationsNCT07292168
Recruiting
Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca468 enrolled123 locationsNCT04482309
Recruiting
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia
Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
AstraZeneca2,000 enrolled41 locationsNCT05887011
Recruiting
Phase 2
Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
Metastatic Cutaneous MelanomaMetastatic Non-small Cell Lung Cancer (NSCLC)
EuroCityClinic LLC90 enrolled1 locationNCT07130032
Recruiting
Phase 2
BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
Biocad124 enrolled47 locationsNCT07108309
Recruiting
Not Applicable
Carbon Suspension vs. Metallic Marker for Axillary Lymph Node Marking in Breast Cancer After Neoadjuvant Therapy
Breast Cancer
Saint Petersburg State University, Russia110 enrolled1 locationNCT07106112
Recruiting
Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Pancreatic CancerGastric CancerLung Cancer+15 more
Apollomics Inc.497 enrolled35 locationsNCT03175224
Recruiting
Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
CarcinomaNon-Small-Cell Lung
AstraZeneca324 enrolled283 locationsNCT05261399
Recruiting
Phase 3
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
Mabscale, LLC620 enrolled28 locationsNCT05654454
Recruiting
Phase 2
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Lung CancerMelanomaPancreas Cancer+4 more
N.N. Petrov National Medical Research Center of Oncology20 enrolled1 locationNCT06229340
Recruiting
Not Applicable
Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)
Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB
N.N. Petrov National Medical Research Center of Oncology60 enrolled1 locationNCT04293796